Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2603 | Problem-solving and relationship improvement intervention. Wiki | 0.45 |
drug726 | Change in preference to surgery under COVID-19 pandemic. Wiki | 0.45 |
drug1801 | Local standard of care Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
drug3282 | Telehealth coaching sessions Wiki | 0.45 |
drug2980 | Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] Wiki | 0.45 |
drug786 | Cognitive and behavioral intervention. Wiki | 0.45 |
drug3850 | life questionnaires Wiki | 0.45 |
drug2848 | Ruxolitinib 5 MG Wiki | 0.45 |
drug1211 | Exercise training group Wiki | 0.45 |
drug782 | Co-mestring (co-coping) Wiki | 0.45 |
drug4030 | standard therapy Wiki | 0.26 |
drug791 | Colchicine Wiki | 0.24 |
drug3976 | questionnaire Wiki | 0.15 |
Name (Synonyms) | Correlation | |
---|---|---|
D000071069 | Multiple Chronic Conditions NIH | 0.45 |
D000073296 | Noncommunicable Diseases NIH | 0.32 |
D008269 | Macular Edema NIH | 0.32 |
Name (Synonyms) | Correlation | |
---|---|---|
D051436 | Renal Insufficiency, Chronic NIH | 0.26 |
D011111 | Polymyalgia Rheumatica NIH | 0.26 |
D013700 | Giant Cell Arteritis NIH | 0.26 |
D007154 | Immune System Diseases NIH | 0.20 |
D007674 | Kidney Diseases NIH | 0.20 |
D009103 | Multiple Sclerosis NIH | 0.17 |
D000066553 | Problem Behavior NIH | 0.15 |
D001523 | Mental Disorders NIH | 0.10 |
D007249 | Inflammation NIH | 0.08 |
D002318 | Cardiovascular Diseases NIH | 0.08 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0011505 | Cystoid macular edema HPO | 0.32 |
HP:0012622 | Chronic kidney disease HPO | 0.32 |
HP:0000077 | Abnormality of the kidney HPO | 0.22 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000708 | Behavioral abnormality HPO | 0.15 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.07 |
Navigate: Correlations HPO
There are 5 clinical trials
A dynamic analytical tool is being implemented to monitor the health, psychosocial and economic impacts of the COVID-19 pandemic as the crisis unfolds. A longitudinal survey is distributed via a network of hospitals, provincial/national organizations and web platforms. The survey information can be linked to provincial health administrative data and metrics derived from social media activity based on artificial intelligence methods. Targeted questions are included for critical populations such as healthcare workers and people with chronic illnesses.
Description: Cohen's Perceived Stress Scale (scores ranged from 0 to 40, higher scores indicating worse stress)
Measure: Mental health - Stress Time: through study completion, estimated to 8 monthsDescription: Generalized Anxiety Disorder Scale (scores ranged from 0 to 21, higher scores indicating worse anxiety)
Measure: Mental health - Anxiety Time: through study completion, estimated to 8 monthsDescription: Quick Inventory of Depressive Symptomatology-Self-report, short version (scores ranged from 0 to 27, higher scores indicating worse depression)
Measure: Mental health - Depression Time: through study completion, estimated to 8 monthsDescription: Measure of Moral Distress - Healthcare Professionals (scores ranged from 0 to 432, higher scores indicating worse moral distress)
Measure: Moral distress in healthcare workers Time: through study completion, estimated to 8 monthsDescription: Rushton Moral Resilience Scale (scores ranged from 1 to 4, higher scores indicating more resiliency)
Measure: Moral resilience in healthcare workers Time: through study completion, estimated to 8 monthsDescription: Frequency of interacting with other people (daily, weekly, monthly, less often than monthly)
Measure: Social life Time: through study completion, estimated to 8 monthsDescription: Fever, Cough, Difficulty breathing or shortness of breath, Tiredness, Aches and pains, Nasal congestion, Runny nose, Sore throat, Diarrhea (Mild Moderate, Severe, N/A)
Measure: COVID-9 symptoms Time: through study completion, estimated to 8 monthsDescription: Mortality (Yes/No): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Adverse health long-term outcome Time: 5 years before the outbreak and two years afterDescription: Hospitalizations (total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Health care utilization - Inpatient Time: 5 years before the outbreak and two years afterDescription: Emergency Department visits (Total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Health care utilization - ER Time: 5 years before the outbreak and two years afterDescription: Outpatient visits: https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Health care utilization - Outpatient Time: 5 years before the outbreak and two years afterDescription: Pittsburgh Sleep Quality Index (scores ranged from 0 to 21, higher scores indicating worse sleep disturbances)
Measure: Sleep Time: through study completion, estimated to 8 monthsThe containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation. Our hypothesis is that in patients with chronic diseases, confinement leads to changes in health behaviours, adherence to pharmacological treatment, lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short, medium and long term. Some messages about the additional risk/danger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17, 2020, the date on which containment began in France. This is the case, for example, for corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major classes of drugs are widely prescribed in patients with chronic diseases, diseases specifically selected in our study (corticosteroids: haematological malignancies, multiple sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this antiplatelet agent, which must be taken for life after an infarction, exposes the patient to a major risk of a new cardiovascular event. The current difficulty of access to care due to travel restrictions (a theoretical limit in the context of French confinement but a priori very real), the impossibility of consulting overloaded doctors, or the cancellation of medical appointments, medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring. Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease, heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health impact of the containment related to the COVID-19 pandemic.
Description: increase in dose, decrease in dose, discontinuation or no change for each drug class)
Measure: % adherence to each pharmacological class Time: during the period from 20 April 2020 to 7 May 2020Description: (mortality, hospitalizations and relevant criteria for each pathology all related to the chronic disease)
Measure: number of occurrence of medical events at 1 year Time: throughout the study for 12 monthsDescription: Smoking/Smoking/sweetening, Alcohol consumption/recovery, Decreased physical activity, Weight change
Measure: Expressed in %: Non-pharmacological treatment/lifestyle: Time: during the period from 20 April 2020 to 7 May 2020As of May 30th more than 23,000 cases of COVID -19 cases were confirmed in Egypt with total deaths of 913. Post viral entry, intense immune response against the virus with infiltration of monocytes and macrophages into alveolar cells with decreasing number of lymphocytes in peripheral blood along with reduced lymphocytes in lymphoid organs, hypercoagulability, thrombosis and multiple organ damage, The gut microbiota and immune homeostasis seem to have a back and forth relationship. Also, gut microbiota derived signals are known to tune the immune cells for pro and anti-inflammatory responses thereby affecting the susceptibility to various diseases. Healthy gut microbiome essentially could be pivotal in maintaining an optimal immune system to prevent an array of excessive immune reactions that eventually become detrimental to lungs and vital organ systems. Numerous studies have shown that the patient's nutritional status have a significant effect on an individual's immunity and over all health status and it has been suggested that nutritional deficiencies may predispose to severe forms of COVID-19 infections. Co-existing non-communicable chronic diseases (NCDs) in COVID-19 patients have been found to delay patients recovery and worsen their prognosis, the reason may be due to aggravated inflammatory pathology found in NCDs exacerbating COVID-19 infection. The aim of the study is to evaluate the role dietary habits among COVID-19 Egyptian patients and whether type of diet (Mediterranean or Western) will affect disease outcomes
Description: To assess the relation between type of diet in mild to moderate COVID 19, to the fate of their course; either improvement or progression
Measure: Western versus Mediterranean diet in COVID-19 outcome Time: 2 monthsDescription: To asses any possible links between gut microbiome and the lung affecting clinical presentation of mild to moderate COVID cases; as diarrhea, loss of taste or smell
Measure: Gut- Lung axis in COVID-19 Time: 2 monthsDescription: Possible protective effects of minerals and vitamins against COVID-19 respiratory illness
Measure: Protective role of minerals and vitamins in COVID-19 patients Time: 2 monthsDescription: Trying to explain the link between non-communicable disease severity and COVID-19 prognosis
Measure: non-communicable diseases and COVID-19 Time: 2 monthsData show that the coronavirus disease 2019 (COVID-19) symptoms can be severe in 4% and 3% of the adolescents aged 11-15 years and ≥ 16 years, respectively. In addition, the prevalence of chronic diseases among adolescents has increased in the last years. About 20% of the adolescents have some chronic disease, resulting in increased morbidity and mortality. In march, 2020, the quarantine was officially implemented in Sao Paulo, while elective medical appointments for adolescents with chronic disease were temporarily suspended. To mitigate the deleterious effect of the social isolation on physical and mental health among these patients, this study aims to test the effects of an online, home-based, exercise training program.
Description: Semi structured interview
Measure: Safety and efficacy of a home-based exercise training program Time: From baseline to 3 months of follow-upDescription: Semi structured interview
Measure: Patients perceptions during social isolation Time: From baseline to 3 months of follow-upDescription: Quality of life will be assessed by means of Pediatric Quality of Life inventory (PedsQLTM 4.0)
Measure: Adolescents quality of life Time: From baseline to 3 months of follow-upDescription: Will be assessed by means of a visual analog scale (from 0 - no disease activity) to 10 - maximum disease activity).
Measure: Disease activity Time: From baseline to 3 months of follow-upDescription: Will be assessed using the visual analog scale from 0 (very good condition) to 10 (very poor condition).
Measure: Disease overall assessment Time: From baseline to 3 months of follow-upDescription: Will be assessed by means of Strengths & Difficulties Questionnaires
Measure: Strengths and difficulties Time: From baseline to 3 months of follow-upThe purpose of this study is to ensure effective health management among community-living older adults during unprecedented times, such as the current COVID-19 pandemic.
Description: Health Education Impact Questionnaire (HeiQ) that evaluates health directed behaviour for chronic disease management.
Measure: Change from baseline: Health Directed Behaviour at 2 months Time: Baseline, Post-intervention (immediately after the 2-month intervention)Description: 21-item survey scale that looks at perceived depression, anxiety and stress.
Measure: Depression, Anxiety, Stress Scale Time: Baseline, Post-intervention (immediately after the 2-month intervention)Description: 19-item survey that evaluates perceived social support.
Measure: Medical Outcomes Study (MOS): Social Support Survey Time: Baseline, Post-intervention (immediately after the 2-month session)Description: Survey scale that evaluates at health-related quality of life.
Measure: Medical Outcomes Study (MOS): Short Form-36 Time: Baseline, Post-intervention (immediately after the 2-month session)Description: 28-item survey scale that looks at health promotion self-efficacy.
Measure: Self-Rated Abilities for Health Practices Scale Time: Baseline, Post-intervention (immediately after the 2-month session)Description: Health Education Impact Questionnaire
Measure: Self-management Time: Baseline, Post-intervention (immediately after the 2-month session)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports